Two of our biggest crises—COVID-19 and climate change—lay bare the magical thinking that pervades psychedelic discourse: that individual experiences of oneness will necessarily transform our society for the better.

Rhana Hashemi is the site coordinator for drug and alcohol programs and services for Oakland Unified School District. But, to her students, she is just “the drug lady.”

The Ibogaine Conversation Part 7 | "Prescription is not about accessibility, by definition it’s about restriction. Unless we start to use psychedelics as a way to tear apart these structures and build new ones in their place, then I think it's all a revolving door."

While COMPASS has issued a response defending the validity of its patents, one of the co-inventors says the patent examiner’s opinion is probably “a valid one.”

A legal, regulated cannabis market would help prevent problematic use and give treatment options the radical revamp they need.

The Ibogaine Conversation Part 5 | Thomas Kingsley Brown, PhD, studied the long-term outcomes of people who received ibogaine for the treatment of opioid addiction. We talked about the results.

In response to Psymposia's reporting on outgoing MAPS Canada Executive Director Mark Haden's resignation following a year full of controversies, Haden published a statement entitled “Clarifying Misinformation” that was full of misinformation and factual inaccuracies. In the following article, we set the record straight.

As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”

You might imagine progressive drug laws go hand-in-hand with social democracy. It's not the case in Sweden.